These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

683 related items for PubMed ID: 27406834

  • 1. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S, Tremblay D, Mascarenhas J.
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
    [Abstract] [Full Text] [Related]

  • 2. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX, EURO-SKI investigators.
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M, Efficace F, Colafigli G, Scalzulli E, Di Prima A, Martelli M, Foà R.
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?
    Bansal A, Radich J.
    Curr Opin Hematol; 2016 Mar 15; 23(2):115-20. PubMed ID: 26825700
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C, Bianchini M, Bengió R, Larripa I.
    Blood Cells Mol Dis; 2014 Mar 15; 52(2-3):121-5. PubMed ID: 24091144
    [Abstract] [Full Text] [Related]

  • 13. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Kockerols C, Valk PJM, Janssen JJWM, Hogenbirk P, Cornelissen JJ, Saussele S, Spiess B, Perusini MA, Kim D, Westerweel PE.
    Eur J Haematol; 2024 Nov 15; 113(5):606-613. PubMed ID: 38994654
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
    Cortes J, Radich J, Mauro MJ.
    Clin Adv Hematol Oncol; 2012 Oct 15; 10(10 Suppl 19):1-16. PubMed ID: 23187745
    [Abstract] [Full Text] [Related]

  • 16. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
    Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW.
    Haematologica; 2016 Jun 15; 101(6):717-23. PubMed ID: 26888022
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Lee B, Kim JA, Kim HS, Cho EH, Kwak JY.
    Acta Haematol; 2016 Jun 15; 135(3):133-9. PubMed ID: 26535871
    [Abstract] [Full Text] [Related]

  • 18. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
    Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE.
    BMC Cancer; 2018 Apr 02; 18(1):359. PubMed ID: 29609532
    [Abstract] [Full Text] [Related]

  • 19. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
    Markovic U, Bulla A, Leotta S, Stella S, Consoli ML, TambÈ L, Conticello C, DI Raimondo F, Stagno F.
    Anticancer Res; 2020 Sep 02; 40(9):5313-5317. PubMed ID: 32878823
    [Abstract] [Full Text] [Related]

  • 20. Treatment-free remission in chronic myeloid leukemia.
    Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ.
    Clin Adv Hematol Oncol; 2019 Dec 02; 17(12):686-696. PubMed ID: 31851157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.